Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer.

Trial Profile

Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer.

Completed
Phase of Trial: Phase 0

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Bicalutamide (Primary) ; Raloxifene (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top